Latest news with #RogerSong
Yahoo
26-06-2025
- Business
- Yahoo
Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5, setting a price target of $79.00. The analyst reasoned that Structure Therapeutics Inc. (NASDAQ:GPCR) is poised to experience a catalyst-rich H2 2025 as its clinical trials are expected to undergo significant developments. Management expects two Phase 2b readouts in Q4, along with the initiation of the amylin first-in-human study by the end of the year. A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses. According to Song, these milestones are critical as they can determine the safety and efficacy of the compounds, especially the '1290 compound, with the potential to differentiate from competitors. Structure Therapeutics Inc. (NASDAQ:GPCR) is also exploring strategic partnerships for commercialization and ensuring manufacturing readiness as part of strategic preparations for Phase 3 trials. The analyst considers it well-positioned to capitalize on emerging opportunities and advance its clinical programs, supported by a cash runway extending to 2027. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops novel oral therapeutics for the treatment of a range of chronic diseases with unmet medical needs. The company's pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5, setting a price target of $79.00. The analyst reasoned that Structure Therapeutics Inc. (NASDAQ:GPCR) is poised to experience a catalyst-rich H2 2025 as its clinical trials are expected to undergo significant developments. Management expects two Phase 2b readouts in Q4, along with the initiation of the amylin first-in-human study by the end of the year. A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses. According to Song, these milestones are critical as they can determine the safety and efficacy of the compounds, especially the '1290 compound, with the potential to differentiate from competitors. Structure Therapeutics Inc. (NASDAQ:GPCR) is also exploring strategic partnerships for commercialization and ensuring manufacturing readiness as part of strategic preparations for Phase 3 trials. The analyst considers it well-positioned to capitalize on emerging opportunities and advance its clinical programs, supported by a cash runway extending to 2027. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops novel oral therapeutics for the treatment of a range of chronic diseases with unmet medical needs. The company's pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
11-04-2025
- Business
- Yahoo
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00
Shares of Nektar Therapeutics (NKTR, Financials) rose 26.21% to $0.50 as of 11:36 a.m. ET Friday after Jefferies upgraded the stock from Hold to Buy and increased its price target from $1.00 to $2.00. The firm's revised rating comes ahead of the expected second-quarter topline data from a Phase 2b study of Rezpeg, Nektar's experimental treatment for atopic dermatitis. Warning! GuruFocus has detected 7 Warning Signs with NKTR. The company has lost over 63% of its market value in the past six months, but Jefferies analyst Roger Song cited encouraging results from a Phase 1b trial, which showed a favorable safety and efficacy profile for Rezpeg, an IL-2 Treg stimulator. Song said the drug's novel mechanism of action sets it apart from other current and pipeline treatments in the space. According to Jefferies, the significant negative enterprise value and high liquidityreflected in a current ratio of 4.26support a more favorable risk-reward scenario. Nektar's market capitalization is currently around $93 million. The firm also pointed to Nektar's cash position of $269.1 million at the end of 2024, which is expected to fund operations through the fourth quarter of 2026. The company recently beat consensus earnings expectations, reporting a fourth-quarter 2024 earnings per share of $0.03, compared with an anticipated loss of $0.16. However, revenue for the quarter came in slightly below forecast at $29.2 million versus $29.81 million. Nektar has entered a $75 million equity distribution agreement to support its financial flexibility. The biotech firm is progressing with clinical development for Rezpeg, which is also being studied for alopecia areata and Type 1 diabetes. Other analysts have issued varying outlooks. Oppenheimer raised its rating to Outperform with a $6.00 price target, while BTIG maintained a Neutral stance with a $4.00 target. This article first appeared on GuruFocus.
